Back to results
US 2024/0252537 A1Published application
Precision molecular adaptor system for car-t immunotherapy
AssigneeGencyte Therapeutics, Inc.
InventorChuhua Zhong
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for immunotherapy including a modular CAR (mCAR) and a precision molecular adaptor (PMA) for targeting the modular CAR-T cells to one or more tumor antigen(s).
Claims11
A precision molecular adaptor (PMA) comprising:
- 1 (a) a recognition moiety comprising a member of the group consisting of indocyanine green (ICG), and an ICG derivative, and, attached to the recognition moiety, (b) an antigen-binding moiety comprising a first antigen recognition domain that binds specifically to a first target antigen.
A method of making a PMA comprising:
- providing an antigen-binding moiety comprising a first antigen recognition domain that binds specifically to a first target antigen, and attaching to the antigen-binding moiety a recognition moiety comprising a member of the group consisting of indocyanine green (ICG) moiety, and an ICG derivative.
8-25. (canceled)
A kit for producing a precision molecular adaptor (PMA), the kit comprising:
- a first component comprising a member of the group consisting of indocyanine green (ICG) moiety, and an ICG derivative, and a second component comprising an antigen-binding moiety comprising a first antigen recognition domain that binds specifically to a first target antigen, and a container for said first and second components, wherein said PMA comprises said first component attached to said second component.
(canceled)
Dependencies are inferred from the claim text.